Company Profile
Novogene provides genomic services and solutions in Mainland China, Hong Kong, Macau, Taiwan, and globally. The company offers genomic solutions comprising human, animal, plant, and microbial whole genome sequencing Human and mouse whole exome sequencing, microbial de novo sequencing, animal and plant de novo sequencing, and 16S/18S/ITS amplicon and shotgun metagenomic sequencing.
Its portfolio also includes transcriptomics solutions, such as mRNA, long non-coding RNA, small RNA, circular RNA, whole transcriptome, isoform, direct RNA, prokaryotic RNA, and meta transcriptome sequencing, and single cell gene expression, single cell long road read transcriptome, and visium formalin-fixed paraffin-embedded spatial transcriptome solutions
Epigenomic solutions comprising whole genome bisulfite, reduced representation bisulfite, chromatin immunoprecipitation, and RNA immunoprecipitation sequencing. Its portfolio also includes premade library and proteomics services, clinical diagnostics services, such as clinical whole exome sequencing and clinical panels, biopharma services consisting of discovery and pre-clinical, translational and clinical, and companion diagnostics, and support services.
Additionally, it offers sequencing platforms under the ILLUMINA, PACBIO, 10X GENOMICS, and NANOPORE brands basic scientific research services in life sciences, and medical research and technical services.
Its services are used in cancer research, immuno-oncology agrigenomics, environment, food science, human microbiome, plant and animal microbiome, drug discovery and development, and rare and complex diseases applications.
The company serves research universities, research institutes, hospitals, pharmaceutical R&D companies, and agricultural companies. Founded in 2011, Novogene is headquartered in Beijing, China.